Loading…
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
Drug cost and pricing policy S.1339, Pharmacy Benefit Manager Transparency Act and other PBM reforms Discussions regarding pharmaceutical issues related to supply chain S.1067, Ensuring Timely Access to Generics Act of 2023 S.1114, Expanding Access to Low Cost Generics Act of 2023 S.113, Prescription Pricing for the People Act of 2023 S.127, Pharmacy Benefit Transparency Act H.R.830, HELP Copays Act H.R.485, Protecting Health Care for All Patients Act
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
Drug cost and pricing policy S.1339, Pharmacy Benefit Manager Transparency Act and other PBM reforms Discussions regarding pharmaceutical issues related to supply chain S.1067, Ensuring Timely Access to Generics Act of 2023 S.1114, Expanding Access to Low Cost Generics Act of 2023 S.113, Prescription Pricing for the People Act of 2023 S.127, Pharmacy Benefit Transparency Act H.R.830, HELP Copays Act H.R.485, Protecting Health Care for All Patients Act
Drug cost and pricing policy issues Issues regarding coverage, coding, and reimbursement issues Issues regarding Alzheimer's treatments Issues related to the 340B program Medicare reform
Source: Senate LDA
Drug cost and pricing policy S.1339, Pharmacy Benefit Manager Transparency Act and other PBM reforms Discussions regarding pharmaceutical issues related to supply chain S.1067, Ensuring Timely Access to Generics Act of 2023 S.1114, Expanding Access to Low Cost Generics Act of 2023 S.113, Prescription Pricing for the People Act of 2023 S.127, Pharmacy Benefit Transparency Act H.R.830, HELP Copays Act H.R.485, Protecting Health Care for All Patients Act
Drug cost and pricing policy S.1967, PBM Act S.1542, DRUG Act H.R.5539, ORPHAN Cures Act Discussions regarding pharmaceutical issues related to supply chain S.113, Prescription Pricing for the People Act of 2023 H.R.830, HELP Copays Act H.R.485, Protecting Health Care for All Patients Act
Drug cost and pricing policy S.1967, PBM Act S.1542, DRUG Act H.R.5539, ORPHAN Cures Act Discussions regarding pharmaceutical issues related to supply chain S.113, Prescription Pricing for the People Act of 2023 H.R.830, HELP Copays Act H.R.485, Protecting Health Care for All Patients Act
Drug cost and pricing policy S.1339, Pharmacy Benefit Manager Transparency Act and other PBM reforms Discussions regarding pharmaceutical issues related to supply chain S.1067, Ensuring Timely Access to Generics Act of 2023 S.1114, Expanding Access to Low Cost Generics Act of 2023 S.113, Prescription Pricing for the People Act of 2023 S.127, Pharmacy Benefit Transparency Act H.R.830, HELP Copays Act H.R.485, Protecting Health Care for All Patients Act
Drug cost and pricing policy S.1339, Pharmacy Benefit Manager Transparency Act and other PBM reforms Discussions regarding pharmaceutical issues related to supply chain S.1067, Ensuring Timely Access to Generics Act of 2023 S.1114, Expanding Access to Low Cost Generics Act of 2023 S.113, Prescription Pricing for the People Act of 2023 S.127, Pharmacy Benefit Transparency Act H.R.830, HELP Copays Act H.R.485, Protecting Health Care for All Patients Act
Drug cost and pricing policy S.1967, PBM Act S.1542, DRUG Act H.R.5539, ORPHAN Cures Act Discussions regarding pharmaceutical issues related to supply chain S.113, Prescription Pricing for the People Act of 2023 H.R.830, HELP Copays Act H.R.485, Protecting Health Care for All Patients Act
Drug cost and pricing policy S.1339, Pharmacy Benefit Manager Transparency Act and other PBM reforms Discussions regarding pharmaceutical issues related to supply chain S.1067, Ensuring Timely Access to Generics Act of 2023 S.1114, Expanding Access to Low Cost Generics Act of 2023 S.113, Prescription Pricing for the People Act of 2023 S.127, Pharmacy Benefit Transparency Act H.R.830, HELP Copays Act H.R.485, Protecting Health Care for All Patients Act
Drug cost and pricing policy S.1339, Pharmacy Benefit Manager Transparency Act and other PBM reforms Discussions regarding pharmaceutical issues related to supply chain S.1067, Ensuring Timely Access to Generics Act of 2023 S.1114, Expanding Access to Low Cost Generics Act of 2023 S.113, Prescription Pricing for the People Act of 2023 S.127, Pharmacy Benefit Transparency Act H.R.830, HELP Copays Act H.R.485, Protecting Health Care for All Patients Act
Drug cost and pricing policy S.1339, Pharmacy Benefit Manager Transparency Act and other PBM reforms Discussions regarding pharmaceutical issues related to supply chain S.1067, Ensuring Timely Access to Generics Act of 2023 S.1114, Expanding Access to Low Cost Generics Act of 2023 S.113, Prescription Pricing for the People Act of 2023 S.127, Pharmacy Benefit Transparency Act H.R.830, HELP Copays Act H.R.485, Protecting Health Care for All Patients Act
Drug cost and pricing policy S.1339, Pharmacy Benefit Manager Transparency Act and other PBM reforms Discussions regarding pharmaceutical issues related to supply chain S.1067, Ensuring Timely Access to Generics Act of 2023 S.1114, Expanding Access to Low Cost Generics Act of 2023 S.113, Prescription Pricing for the People Act of 2023 S.127, Pharmacy Benefit Transparency Act H.R.830, HELP Copays Act H.R.485, Protecting Health Care for All Patients Act
Drug cost and pricing policy S.1967, PBM Act S.1542, DRUG Act H.R.5539, ORPHAN Cures Act Discussions regarding pharmaceutical issues related to supply chain S.113, Prescription Pricing for the People Act of 2023 H.R.830, HELP Copays Act H.R.485, Protecting Health Care for All Patients Act
Drug cost and pricing policy S.1339, Pharmacy Benefit Manager Transparency Act and other PBM reforms Discussions regarding pharmaceutical issues related to supply chain S.1067, Ensuring Timely Access to Generics Act of 2023 S.1114, Expanding Access to Low Cost Generics Act of 2023 S.113, Prescription Pricing for the People Act of 2023 S.127, Pharmacy Benefit Transparency Act H.R.830, HELP Copays Act H.R.485, Protecting Health Care for All Patients Act
Drug cost and pricing policy S.1339, Pharmacy Benefit Manager Transparency Act and other PBM reforms Discussions regarding pharmaceutical issues related to supply chain S.1067, Ensuring Timely Access to Generics Act of 2023 S.1114, Expanding Access to Low Cost Generics Act of 2023 S.113, Prescription Pricing for the People Act of 2023 S.127, Pharmacy Benefit Transparency Act H.R.830, HELP Copays Act H.R.485, Protecting Health Care for All Patients Act
Discussions regarding drug pricing and supply chain issues, rare diseases, gene therapy and value based arrangements; biosimilar support; Alzheimer's policy, screening and diagnosis, PET scan coverage and reimbursement, and dementia care Inflation Reduction Act implementation (P.L.117-1769), including provisions related to corporate taxes, Medicare, research and development, and prescription drug pricing The Mental Health Professionals Workforce Shortage Loan Repayment Act S.1214, RARE Act Issues related to ALS
Discussions regarding drug pricing and supply chain issues, rare diseases, gene therapy and value based arrangements; biosimilar support; Alzheimer's policy, screening and diagnosis, PET scan coverage and reimbursement, and dementia care Inflation Reduction Act implementation (P.L.117-1769), including provisions related to corporate taxes, Medicare, research and development, and prescription drug pricing The Mental Health Professionals Workforce Shortage Loan Repayment Act S.1214, RARE Act
Discussions regarding drug pricing and supply chain issues, rare diseases, gene therapy and value based arrangements; biosimilar support; Alzheimer's policy, screening and diagnosis, PET scan coverage and reimbursement, and dementia care Inflation Reduction Act implementation (P.L.117-1769), including provisions related to corporate taxes, Medicare, research and development, and prescription drug pricing The Mental Health Professionals Workforce Shortage Loan Repayment Act S.1214, RARE Act
Drug cost and pricing policy S.1339, Pharmacy Benefit Manager Transparency Act and other PBM reforms Discussions regarding pharmaceutical issues related to supply chain S.1067, Ensuring Timely Access to Generics Act of 2023 S.1114, Expanding Access to Low Cost Generics Act of 2023 S.113, Prescription Pricing for the People Act of 2023 S.127, Pharmacy Benefit Transparency Act H.R.830, HELP Copays Act H.R.485, Protecting Health Care for All Patients Act
Drug cost and pricing policy S.127, Pharmacy Benefit Manager Transparency Act and other PBM reforms Discussions regarding pharmaceutical issues related to supply chain
Drug cost and pricing policy S.1339, Pharmacy Benefit Manager Transparency Act and other PBM reforms Discussions regarding pharmaceutical issues related to supply chain S.1067, Ensuring Timely Access to Generics Act of 2023 S.1114, Expanding Access to Low Cost Generics Act of 2023 S.113, Prescription Pricing for the People Act of 2023 S.127, Pharmacy Benefit Transparency Act H.R.830, HELP Copays Act H.R.485, Protecting Health Care for All Patients Act
Drug cost and pricing policy S.1339, Pharmacy Benefit Manager Transparency Act and other PBM reforms Discussions regarding pharmaceutical issues related to supply chain S.1067, Ensuring Timely Access to Generics Act of 2023 S.1114, Expanding Access to Low Cost Generics Act of 2023 S.113, Prescription Pricing for the People Act of 2023 S.127, Pharmacy Benefit Transparency Act H.R.830, HELP Copays Act H.R.485, Protecting Health Care for All Patients Act
Drug cost and pricing policy S.1339, Pharmacy Benefit Manager Transparency Act and other PBM reforms Discussions regarding pharmaceutical issues related to supply chain S.1067, Ensuring Timely Access to Generics Act of 2023 S.1114, Expanding Access to Low Cost Generics Act of 2023 S.113, Prescription Pricing for the People Act of 2023 S.127, Pharmacy Benefit Transparency Act H.R.830, HELP Copays Act H.R.485, Protecting Health Care for All Patients Act
Drug cost and pricing policy S.1967, PBM Act S.1542, DRUG Act H.R.5539, ORPHAN Cures Act Discussions regarding pharmaceutical issues related to supply chain S.113, Prescription Pricing for the People Act of 2023 H.R.830, HELP Copays Act H.R.485, Protecting Health Care for All Patients Act
Drug cost and pricing policy S.1967, PBM Act S.1542, DRUG Act H.R.5539, ORPHAN Cures Act Discussions regarding pharmaceutical issues related to supply chain S.113, Prescription Pricing for the People Act of 2023 H.R.830, HELP Copays Act H.R.485, Protecting Health Care for All Patients Act
Discussions regarding drug pricing and supply chain issues, rare diseases, gene therapy and value based arrangements; biosimilar support; Alzheimer's policy, PET scan coverage and reimbursement, and dementia care H.R.19, Lower Costs, More Cures Act of 2021 H.R. 5376, Inflation Reduction Act (Build Back Better Act), including provisions related to corporate taxes, Medicare, and prescription drug pricing H.R.7667, Food and Drug Amendments of 2022 User Fee Agreements, specifically reauthorization of PDUFA and BSUFA Aduhelm National Coverage Determination
Discussions regarding drug pricing and supply chain issues, rare diseases, gene therapy and value based arrangements; biosimilar support; Alzheimer's policy, PET scan coverage and reimbursement, and dementia care H.R.19, Lower Costs, More Cures Act of 2021 H.R. 5376, Inflation Reduction Act, including provisions related to corporate taxes, Medicare, and prescription drug pricing H.R.7667, Food and Drug Amendments of 2022 User Fee Agreements, specifically reauthorization of PDUFA and BSUFA Aduhelm National Coverage Determination
H.R.3/S.2543, Elijah E. Cummings Lower Drug Costs Now Act, discussions regarding support to increase Part B biosimilar payments from ASP +6% to ASP +8% of the reference product Issue regarding COVID-19, supply chain, pharmaceutical pricing and drug development lifecycle
Discussions regarding drug pricing and supply chain issues, rare diseases, gene therapy and value based arrangements; biosimilar support; Alzheimer's policy, PET scan coverage and reimbursement, and dementia care H.R.19, Lower Costs, More Cures Act of 2021 H.R. 5376, Inflation Reduction Act (Build Back Better Act), including provisions related to corporate taxes, Medicare, and prescription drug pricing H.R.7667, Food and Drug Amendments of 2022 User Fee Agreements, specifically reauthorization of PDUFA and BSUFA Aduhelm National Coverage Determination
Discussions regarding drug pricing and supply chain issues, rare diseases, gene therapy and value based arrangements; biosimilar support; Alzheimer's policy, PET scan coverage and reimbursement, and dementia care H.R.19, Lower Costs, More Cures Act of 2021 H.R. 5376, Inflation Reduction Act, including provisions related to corporate taxes, Medicare, and prescription drug pricing H.R.7667, Food and Drug Amendments of 2022 User Fee Agreements, specifically reauthorization of PDUFA and BSUFA Aduhelm National Coverage Determination
Discussions regarding drug pricing and supply chain issues, rare diseases, gene therapy and value based arrangements; biosimilar support; Alzheimer's policy, PET scan coverage and reimbursement, and dementia care H.R.19, Lower Costs, More Cures Act of 2021 H.R. 5376, Inflation Reduction Act (Build Back Better Act), including provisions related to corporate taxes, Medicare, and prescription drug pricing H.R.7667, Food and Drug Amendments of 2022 User Fee Agreements, specifically reauthorization of PDUFA and BSUFA Aduhelm National Coverage Determination
Discussions regarding drug pricing and supply chain issues, rare diseases, gene therapy and value based arrangements; biosimilar support; Alzheimer's policy, PET scan coverage and reimbursement, and dementia care H.R.19, Lower Costs, More Cures Act of 2021 H.R. 5376, Inflation Reduction Act, including provisions related to corporate taxes, Medicare, and prescription drug pricing H.R.7667, Food and Drug Amendments of 2022 User Fee Agreements, specifically reauthorization of PDUFA and BSUFA Aduhelm National Coverage Determination
A bill to require a study on the national security implications of the People's Republic of China's efforts to create an official digital currency.
H.R.3/S.2543, Elijah E. Cummings Lower Drug Costs Now Act, discussions regarding support to increase Part B biosimilar payments from ASP +6% to ASP +8% of the reference product Issue regarding COVID-19, supply chain, pharmaceutical pricing and drug development lifecycle
Discussions regarding drug pricing and supply chain issues, rare diseases, gene therapy and value based arrangements; biosimilar support; Alzheimer's policy, screening and diagnosis, PET scan coverage and reimbursement, and dementia care Inflation Reduction Act implementation (P.L.117-1769), including provisions related to corporate taxes, Medicare, research and development, and prescription drug pricing The Mental Health Professionals Workforce Shortage Loan Repayment Act S.1214, RARE Act
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
Discussions regarding drug pricing and supply chain issues, rare diseases, gene therapy and value based arrangements; biosimilar support; Alzheimer's policy, screening and diagnosis, PET scan coverage and reimbursement, and dementia care Inflation Reduction Act implementation (P.L.117-1769), including provisions related to corporate taxes, Medicare, research and development, and prescription drug pricing The Mental Health Professionals Workforce Shortage Loan Repayment Act S.1214, RARE Act Issues related to ALS
Drug cost and pricing policy S.1967, PBM Act S.1542, DRUG Act H.R.5539, ORPHAN Cures Act Discussions regarding pharmaceutical issues related to supply chain S.113, Prescription Pricing for the People Act of 2023 H.R.830, HELP Copays Act H.R.485, Protecting Health Care for All Patients Act
Drug cost and pricing policy issues Issues related to the 340B program
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
Drug cost and pricing policy issues Issues regarding coverage, coding, and reimbursement issues Issues regarding Alzheimer's treatments Issues related to the 340B program Medicare reform
Drug cost and pricing policy S.1339, Pharmacy Benefit Manager Transparency Act and other PBM reforms Discussions regarding pharmaceutical issues related to supply chain S.1067, Ensuring Timely Access to Generics Act of 2023 S.1114, Expanding Access to Low Cost Generics Act of 2023 S.113, Prescription Pricing for the People Act of 2023 S.127, Pharmacy Benefit Transparency Act H.R.830, HELP Copays Act H.R.485, Protecting Health Care for All Patients Act
Discussions regarding drug pricing and supply chain issues, rare diseases, gene therapy and value based arrangements; biosimilar support; Alzheimer's policy, screening and diagnosis, PET scan coverage and reimbursement, and dementia care Inflation Reduction Act implementation (P.L.117-1769), including provisions related to corporate taxes, Medicare, research and development, and prescription drug pricing The Mental Health Professionals Workforce Shortage Loan Repayment Act S.1214, RARE Act
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
Discussions regarding drug pricing and supply chain issues, rare diseases, gene therapy and value based arrangements; biosimilar support; Alzheimer's policy, screening and diagnosis, PET scan coverage and reimbursement, and dementia care Inflation Reduction Act implementation, including provisions related to corporate taxes, Medicare, and prescription drug pricing Mental Health Workforce Expansion The Mental Health Professionals Workforce Shortage Loan Repayment Act HELP Copays Act Issues related to ALS
Drug cost and pricing policy issues Issues regarding coverage, coding, and reimbursement issues Issues regarding Alzheimer's treatments Issues related to the 340B program
Drug cost and pricing policy S.127, Pharmacy Benefit Manager Transparency Act and other PBM reforms Discussions regarding pharmaceutical issues related to supply chain
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
Drug cost and pricing policy issues Issues regarding coverage, coding, and reimbursement issues Issues regarding Alzheimer's treatments
Drug cost and pricing policy Patient affordability issues policy proposals related to clinical trial diversity Issues related to the 340B program
Discussions regarding drug pricing and supply chain issues, rare diseases, gene therapy and value based arrangements; biosimilar support; Alzheimer's policy, PET scan coverage and reimbursement, and dementia care H.R.19, Lower Costs, More Cures Act of 2021 H.R. 5376, Inflation Reduction Act, including provisions related to corporate taxes, Medicare, and prescription drug pricing H.R.7667, Food and Drug Amendments of 2022 User Fee Agreements, specifically reauthorization of PDUFA and BSUFA Aduhelm National Coverage Determination
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
H.R.3/S.2543, Elijah E. Cummings Lower Drug Costs Now Act, discussions regarding support to increase Part B biosimilar payments from ASP +6% to ASP +8% of the reference product Issue regarding COVID-19, supply chain, pharmaceutical pricing and drug development lifecycle
Issues regarding coverage, coding, and reimbursement issues Issues regarding Alzheimer's treatments
Discussions regarding drug pricing and supply chain issues, rare diseases, gene therapy and value based arrangements; biosimilar support; Alzheimer's policy, PET scan coverage and reimbursement, and dementia care H.R.19, Lower Costs, More Cures Act of 2021 H.R. 5376, Inflation Reduction Act (Build Back Better Act), including provisions related to corporate taxes, Medicare, and prescription drug pricing H.R.7667, Food and Drug Amendments of 2022 User Fee Agreements, specifically reauthorization of PDUFA and BSUFA Aduhelm National Coverage Determination
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE